Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.

@article{Gharbiya2009IntravitrealBT,
  title={Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.},
  author={Magda Gharbiya and Francesca Allievi and L Moronetti Mazzeo and Corrado Balacco Gabrieli},
  journal={American journal of ophthalmology},
  year={2009},
  volume={147 1},
  pages={84-93.e1}
}
PURPOSE To evaluate the short-term efficacy and safety of intravitreal bevacizumab for the treatment of myopic choroidal neovascularization (CNV). DESIGN Prospective, nonrandomized, interventional case series. METHODS Twenty eyes from 20 patients with CNV secondary to pathologic myopia participated in this prospective nonrandomized interventional case series. All patients were scheduled for three monthly intravitreal bevacizumab 1.25 mg injections. Early Treatment Diabetic Retinopathy Study… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

References

Publications referenced by this paper.

Similar Papers

Loading similar papers…